Kidney Week

Abstract: SA-PO206

Psychiatric Disorders in Onconephrology Patients: Prevalence, Impact on Survival, and Quality of Life

Session Information

• Onconephrology: Kidney Outcomes during Cancer Treatment and Nephropathies
  October 26, 2024 | Location: Exhibit Hall, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Onconephrology

• 1700 Onconephrology

Authors

• Zamora Carrillo, Jorge Ivan, Hospital Universitari Vall d'Hebron, Barcelona, Catalunya, Spain

Jorge Ivan Zamora Carrillo, MD

• Bermejo Garcia, Sheila, Vall D’hebron Institut de Recerca (VHIR),, Barcelona, Barcelona, Spain

Sheila Bermejo Garcia, MD, DrMed, PhD

• Callejo, Ana, Hospital Universitari Vall d'Hebron, Barcelona, Catalunya, Spain

Ana Callejo, MD

• López-Martínez, Marina, Hospital Universitari Vall d'Hebron, Barcelona, Catalunya, Spain

Marina López-Martínez, MD

• León-Román, Juan Carlos, Hospital Universitari Vall d'Hebron, Barcelona, Catalunya, Spain

Juan Carlos León-Román, MD

• Patricio-Liébana, Marc, Hospital Universitari Vall d'Hebron, Barcelona, Catalunya, Spain

Marc Patricio-Liébana, MD

• Soler, Maria Jose, Hospital Universitari Vall d'Hebron, Barcelona, Catalunya, Spain

Maria Jose Soler, MD, PhD

Background

Onconephrology has emerged as a crucial subspecialty. Psychiatric disorders are common in cancer and kidney patients, but their impact in Onconephrology patients is not known. The aims of study are to investigate the prevalence and impact of psychiatric disorders on survival and quality of life in Onconephrology patients.

Methods

This prospective study included patients from the Onconephrology Unit (Nov-2021 to Feb-2023). Questionnaires assessed sleep disorders (Epworth scale), depression (GDS, PHQ), cognition (Montreal scale), and anxiety (GAD) at the first visit, 6 months, and 12 months. Clinical and analytical characteristics were collected.

Results

182 patients were included (mean age 68(±11) years, 70(38.5%) women). 18(9.9%) lived alone, 152(83.5%) lived accompanied and 4(2.2%) in residence. At the first visit, (81)44.5% had sleep disorders, 52(32.7%) depression, 72(39.6%) cognitive impairment, and 14(7.7%) anxiety. Depression was more prevalent in people who lived in residence (p=0.013). Patients with cognitive impairment had a higher prevalence of DM(p=0.003), worse kidney function and were older(p<0.001). Sleep disorders were more prevalent in older patients(p=0.01), and anxiety in women(p<0.001). At six months, anxiety was higher in women(p=0.03) and those with progressive oncological disease(p<0.001). Living alone was linked to more depression(p=0.002). At twelve months, depression correlated with oncological progression(p=0.034). Multivariate analysis identified age as a risk factor for cognitive impairment(OR: 1.1; p<0.001) and female sex for depression(OR: 3.39; p=0.001). At 6 months, female sex was a risk factor for anxiety(OR: 8.6; p=0.01) and living alone for depression(OR: 10.8; p<0.001). 30(16.5%) patients died during follow-up. Kaplan-Meier analysis showed higher mortality in patients with sleep disorders(p=0.039), worse kidney function(p=0.003), and progressive disease(p=0.028)

Conclusion

Onconephrology patients had high rates of depression and anxiety, especially females and people living alone. Comprehensive approaches and early detection tools are essential to improve their survival and quality of life.